Literature DB >> 11069722

Prostaglandins regulate melanoma-induced cytokine production in macrophages.

C A Eisengart1, J R Mestre, H A Naama, P J Mackrell, D E Rivadeneira, E M Murphy, P P Stapleton, J M Daly.   

Abstract

Tumor-secreted products can affect macrophage cytokine expression and in that way alter the immune response. Prostaglandins (PGs) are found in the tumor microenvironment and have been associated with local and regional immunosuppression. We investigated whether tumor-secreted factors could induce PG synthesis in macrophages and whether these PGs could alter macrophage production of immunoregulatory cytokines. In both murine and human models, melanoma conditioned medium (MCM) induced macrophage production of PGE(2), IL-6, and TNF-alpha. PGE(2) production increased over 24 h and was accompanied by an increase in cyclooxygenase-2 (COX-2) expression, while COX-1 expression remained unchanged. In the presence of 10 microM NS398, a selective COX-2 inhibitor, MCM-stimulated PGE(2) synthesis was almost completely suppressed, while production of IL-6 and TNF-alpha proteins and mRNA also was partially abrogated. In the murine model, 200 microM NS398 resulted in more significant inhibition of cytokine protein and mRNA production. Although MCM induced NFkappaB and NF-IL-6 activation, neither dose of NS398 altered this effect. We conclude that melanoma-secreted products stimulate COX-2 expression and PGE(2) synthesis in macrophages and that inhibition of COX-2-derived PG synthesis results in partial abrogation of macrophage cytokine production. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069722     DOI: 10.1006/cimm.2000.1686

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

Review 1.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  Prostaglandin E2 Regulates Activation of Mouse Peritoneal Macrophages by Staphylococcus aureus through Toll-Like Receptor 2, Toll-Like Receptor 4, and NLRP3 Inflammasome Signaling.

Authors:  Jindi Wu; Bo Liu; Wei Mao; Shuang Feng; Yuan Yao; Fan Bai; Yuan Shen; Amu Guleng; Bayin Jirigala; Jinshan Cao
Journal:  J Innate Immun       Date:  2019-05-29       Impact factor: 7.349

Review 4.  Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.

Authors:  Yunzhou Pu; Qing Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

5.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

6.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031

7.  Procyanidin B3 prevents articular cartilage degeneration and heterotopic cartilage formation in a mouse surgical osteoarthritis model.

Authors:  Hailati Aini; Hiroki Ochi; Munetaka Iwata; Atsushi Okawa; Daisuke Koga; Mutsumi Okazaki; Atsushi Sano; Yoshinori Asou
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

8.  The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.

Authors:  Jean-Claude Marshall; Amanda L Caissie; Stephanie R Cruess; Jonathan Cools-Lartigue; Miguel N Burnier
Journal:  J Carcinog       Date:  2007-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.